Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01120145
Other study ID # CDC-CGH-5756
Secondary ID
Status Completed
Phase N/A
First received May 5, 2010
Last updated February 5, 2013
Start date March 2010
Est. completion date January 2011

Study information

Verified date February 2013
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentMalawi: College of Medicine Research and Ethics Committee
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the efficacy and effectiveness of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy for reducing malaria-associated morbidity in pregnant women in Malawi.


Description:

Malaria infection in pregnancy is associated with severe maternal anemia, placental parasitemia, low birth weight, and increased perinatal mortality. Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is recommended by the World Health Organization (WHO) for reducing the risks associated with malaria in pregnancy. Traditionally, the level of SP resistance has been assessed by monitoring its in vivo efficacy for treatment of uncomplicated malaria in children under five years of age. However, parasite resistance to SP has compromised its efficacy in young children, and SP is no the longer a first-line recommended treatment for malaria in most African countries. Although SP currently appears to remain effective for IPTp in pregnant women probably because they have more immunity than young children, it is important to monitor SP effectiveness in this population. Characterizing SP resistance through in vivo and molecular methods in pregnant women may be useful to predict whether to continue a policy of IPTp with SP.

There will be three parts to this study. To determine therapeutic efficacy of SP IPTp in pregnant women, a prospective in vivo study will be done in women who present for antenatal care (ANC). Women will receive SP IPTp according to national guidelines and will be followed for 42 days for clearance of peripheral parasitemia. To determine birth outcomes of women given SP IPTp, a retrospective cohort study will be performed assessing outcomes of women at delivery. Information on prior receipt of SP IPTp, peripheral and placental parasitemia at delivery, placental histology, maternal anemia, and birth weight will be collected. To characterize baseline resistance of SP in pregnant women and in the general population, parasites will be collected from both participating women and attendees at outpatient clinics to measure SP resistance markers.

The results of this study will be used by the Malawi national control program to evaluate current policy of using SP for IPTp. This study will also contribute towards an international effort led by WHO to align priorities and methodologies in gathering data on the efficacy of SP in IPTp in the face of increasing SP resistance, thus providing data to inform IPTp policy at the global level.


Recruitment information / eligibility

Status Completed
Enrollment 1410
Est. completion date January 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Therapeutic efficacy study

Inclusion Criteria:

- 16-26 weeks gestation based on last menstrual period (LMP) or quickening

- Axillary temperature <37.5 degrees Celsius

- Informed consent

Exclusion Criteria:

- History of hypersensitivity reaction to SP or components of SP

- Axillary temperature =37.5 degrees C

- History of receipt of antimalarials in the past month

- Known HIV infection

Birth outcomes study:

Inclusion Criteria:

- Singleton pregnancy

- SP IPTp history available

- Informed consent

Exclusion Criteria:

- Blood transfusion after the 16th gestational week

- Receipt of antimalarials other than SP for IPTp after 16th gestational week

- Known HIV infection

Characterizing molecular markers of SP resistance:

Inclusion Criteria:

- Outpatient attending selected health facility

- Informed consent

Exclusion Criteria:

Study Design

Observational Model: Cohort


Related Conditions & MeSH terms


Locations

Country Name City State
Malawi Machinga District Hospital Liwonde Machinga District

Sponsors (2)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention University of Malawi College of Medicine

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Primary Therapeutic efficacy study: Development of fever or symptoms of severe malaria (defined by WHO) and parasitemia at any time after the first dose of SP during the 42 day follow up period 42 days No
Primary Birth outcomes study: Evidence of malaria infection based on placental histology at the time of delivery At time of birth No
Primary Characterizing molecular markers of SP resistance: Prevalence of molecular markers of sulphadoxine-pyrimethamine resistance at the time of health facility visit Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT03508349 - Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda N/A
Completed NCT01053325 - Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy Phase 3
Completed NCT00140517 - Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance N/A
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Active, not recruiting NCT01555255 - Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria N/A
Completed NCT01136850 - Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea Phase 3
Terminated NCT04148690 - Assessing the Impact of Group Antenatal Care on IPTp Uptake in Tanzania N/A
Completed NCT04160026 - Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya Phase 4
Completed NCT04783051 - Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) Phase 3
Not yet recruiting NCT05348746 - ERASE - Impact of COVID-19 on Malaria Control
Completed NCT03998839 - TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
Completed NCT03208179 - Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa Phase 3
Completed NCT00730366 - New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa Phase 3
Completed NCT00852423 - Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria Phase 3
Completed NCT00680732 - Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Phase 4
Recruiting NCT03754322 - LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial N/A
Not yet recruiting NCT03944317 - Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP) N/A
Completed NCT05294406 - Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia Phase 4
Recruiting NCT04825782 - MiMBa Pregnancy Registry